Serotonin 5-hydroxytryptamine receptor 1B, 1D, and 1F (5-HT1B, 5-HT1D, 5-HT1F)

The **serotonin 5-hydroxytryptamine receptor 1B, 1D, and 1F** are closely related members of the serotonin receptor family, all classified as G protein-coupled receptors (GPCRs) activated by the neurotransmitter serotonin (5-HT). Each mediates inhibitory neurotransmission primarily in the central and peripheral nervous systems, often by reducing the presynaptic release of serotonin or other neurotransmitters. The 5-HT1B and 5-HT1D receptors are well-characterized for their role in migraine, where they are targets of the 'triptan' class of antimigraine drugs. Agonism at these receptors leads to inhibition of trigeminal nerve-mediated neurogenic inflammation and vasoconstriction of cranial blood vessels, contributing to their therapeutic effect in migraine. These receptors also play important roles in the regulation of mood, anxiety, and vascular tone. Grouping these three receptors (1B, 1D, 1F) is occasionally done in the context of antimigraine pharmacology due to overlapping drug selectivity (for example, newer "ditan" agents are 5-HT1F agonists), but they are encoded by separate genes and have distinct expression patterns, pharmacology, and (in the case of 1F) therapeutic profiles[1][2][3][4][5]. **Note:** While "5-HT1B/1D/1F receptors" is used in some literature to refer to the triptan/ditan target profile, each subtype is a distinct molecular target and typically dealt with individually in rigorous molecular or clinical databases. For structured data, information should ideally be mapped to the specific 5-HT1B receptor, 5-HT1D receptor, and 5-HT1F receptor, not to a lumped "5-HT1B/1D/1F receptors" entry[2][5].

Other names

5-HT1B receptor5-HT1D receptor5-HT1F receptor5-hydroxytryptamine receptor 1B, 1D, 1FSerotonin receptor 1B, 1D, 1F

Agonists activate the receptor, leading to inhibition of adenylate cyclase via Gi proteins, decreasing cAMP in target tissues[2][3][5]. Resultant inhibition of presynaptic neurotransmitter (including serotonin) release[1][2][5]. Vasoconstriction of cranial blood vessels (especially relevant for antimigraine effect)[2][3].